686 related articles for article (PubMed ID: 37059070)
1. Pancreatic cancer: Advances and challenges.
Halbrook CJ; Lyssiotis CA; Pasca di Magliano M; Maitra A
Cell; 2023 Apr; 186(8):1729-1754. PubMed ID: 37059070
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
Tarannum M; Vivero-Escoto JL
Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
[TBL] [Abstract][Full Text] [Related]
3. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.
Shi Y; Gao W; Lytle NK; Huang P; Yuan X; Dann AM; Ridinger-Saison M; DelGiorno KE; Antal CE; Liang G; Atkins AR; Erikson G; Sun H; Meisenhelder J; Terenziani E; Woo G; Fang L; Santisakultarm TP; Manor U; Xu R; Becerra CR; Borazanci E; Von Hoff DD; Grandgenett PM; Hollingsworth MA; Leblanc M; Umetsu SE; Collisson EA; Scadeng M; Lowy AM; Donahue TR; Reya T; Downes M; Evans RM; Wahl GM; Pawson T; Tian R; Hunter T
Nature; 2019 May; 569(7754):131-135. PubMed ID: 30996350
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
5. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
6. Exploring the potential of exosomes in diagnosis and drug delivery for pancreatic ductal adenocarcinoma.
Xu B; Chen Y; Peng M; Zheng JH; Zuo C
Int J Cancer; 2023 Jan; 152(2):110-122. PubMed ID: 35765844
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment.
Wood LD; Canto MI; Jaffee EM; Simeone DM
Gastroenterology; 2022 Aug; 163(2):386-402.e1. PubMed ID: 35398344
[TBL] [Abstract][Full Text] [Related]
8. The biological underpinnings of therapeutic resistance in pancreatic cancer.
Beatty GL; Werba G; Lyssiotis CA; Simeone DM
Genes Dev; 2021 Jul; 35(13-14):940-962. PubMed ID: 34117095
[TBL] [Abstract][Full Text] [Related]
9. Advances in pancreatic cancer research: moving towards early detection.
He XY; Yuan YZ
World J Gastroenterol; 2014 Aug; 20(32):11241-8. PubMed ID: 25170208
[TBL] [Abstract][Full Text] [Related]
10. Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models.
Heinrich MA; Mostafa AMRH; Morton JP; Hawinkels LJAC; Prakash J
Adv Drug Deliv Rev; 2021 Jul; 174():265-293. PubMed ID: 33895214
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue.
Longo V; Brunetti O; Gnoni A; Cascinu S; Gasparini G; Lorusso V; Ribatti D; Silvestris N
Oncotarget; 2016 Sep; 7(36):58649-58658. PubMed ID: 27462915
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
13. Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance.
Sherman MH; Beatty GL
Annu Rev Pathol; 2023 Jan; 18():123-148. PubMed ID: 36130070
[TBL] [Abstract][Full Text] [Related]
14. Targeting pancreatic ductal adenocarcinoma acidic microenvironment.
Cruz-Monserrate Z; Roland CL; Deng D; Arumugam T; Moshnikova A; Andreev OA; Reshetnyak YK; Logsdon CD
Sci Rep; 2014 Mar; 4():4410. PubMed ID: 24642931
[TBL] [Abstract][Full Text] [Related]
15. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma.
Ng CF; Glaspy J; Placencio-Hickok VR; Thomassian S; Gong J; Osipov A; Hendifar AE; Moshayedi N
J Natl Compr Canc Netw; 2022 Oct; 20(10):1076-1079. PubMed ID: 36240849
[TBL] [Abstract][Full Text] [Related]
16. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.
Lafaro KJ; Melstrom LG
Am J Pathol; 2019 Jan; 189(1):44-57. PubMed ID: 30558722
[TBL] [Abstract][Full Text] [Related]
17. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
18. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
[TBL] [Abstract][Full Text] [Related]
19. The next "sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection.
Xu Y; Wang Y; Höti N; Clark DJ; Chen SY; Zhang H
Mass Spectrom Rev; 2023 Mar; 42(2):822-843. PubMed ID: 34766650
[TBL] [Abstract][Full Text] [Related]
20. Mathematical Modeling to Address Challenges in Pancreatic Cancer.
Dogra P; Ramírez JR; Peláez MJ; Wang Z; Cristini V; Parasher G; Rawat M
Curr Top Med Chem; 2020; 20(5):367-376. PubMed ID: 31893993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
